X
Tagrisso on target to be EGFR+ lung cancer standard
https://pharmaphorum.com/news/tagrisso-target-egfr-lung-cancer-standard/
ESMO
Rubraca outshines rivals in ovarian cancer maintenance therapy
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
ESMO 2017 preview: AstraZeneca‘s comeback, IO shifts to earlier use
A look ahead at some of the most eye-catching data and trends at ESMO 2017
pharmaphorum and Symplur launch Conference360 Report
pharmaphorum media and Symplur, LLC launch Conference360 Report to help pharma and other stakeholders understand social media conversations around medical congresses
ESMO review: advances in immunotherapy, EMA dialogue and patient power
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Cancer Market Commentary: Keytruda’s triumph not the last word in NSCLC
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
1 2
